Key result
Three cases illustrate a previously unreported co-occurrence of sporadic late-onset nemaline myopathy and MGUS-associated neuropathy, which may improve with anti-plasma cell therapy.
Why the study?
Although sporadic late-onset nemaline myopathy frequently occurs with MGUS, its coexistence with other MGUS-related disorders had not been reported.
Case Report (n=3)
This case series illustrates a previously unreported co-occurrence of SLONM and MGUS-associated neuropathy, suggesting that clone-directed therapy may provide benefit in progressive cases.
Answers are grounded in this paper and cite their sources.
Reports first SLONM-paraproteinemic neuropathy overlap; leaves open diagnostic criteria and MGUS-directed therapy effects.
Sporadic late-onset nemaline myopathy (SLONM) is an acquired adult-onset myopathy characterized by subacute proximal weakness and nemaline rods in muscle. Although SLONM frequently occurs with monoclonal gammopathy of undetermined significance (MGUS), the coexistence with other MGUS-related disorders has not been reported. We describe three patients with SLONM and paraproteinemic neuropathy, showing sensory involvement and variable motor deficits, from mild non-progressive disease to a severe form with bulbar complications. Muscle histology revealed a significant number of fibres with nemaline rods and also frequent mitochondrial abnormalities, while nerve pathology demonstrated granular endoneurial deposits consistent with immune-complex-mediated neuropathy. One untreated patient remained stable, whereas the other two progressive, immunosuppressive-refractory cases improved with anti-plasma cell therapy. These cases illustrate a previously unreported co-occurrence of SLONM and MGUS-associated neuropathy. Despite differing clinical courses, shared pathology suggests common mechanisms, with mitochondrial abnormalities as a possibly under-recognized feature. Muscle and nerve biopsy including electronmicroscopic analysis is crucial for accurate diagnosis, and clone-directed therapy may provide benefit.
No takes yet. Share an insight, caveat, or question.
Torchia et al. (2025) conducted a case report in Sporadic late-onset nemaline myopathy (SLONM) and paraproteinemic neuropathy (n=3). Anti-plasma cell therapy was evaluated on Clinical improvement. Three cases illustrate a previously unreported co-occurrence of sporadic late-onset nemaline myopathy and MGUS-associated neuropathy, which may improve with anti-plasma cell therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: